Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 363 clinical trials
featured
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

metastatic urothelial carcinoma
bladder cancer
bladder carcinoma
urothelial carcinoma
  • 22 views
  • 14 Dec, 2020
  • 64 locations
featured
A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer

A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer

  • 142 views
  • 08 Nov, 2020
  • 1 location
featured
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)

A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)

  • 196 views
  • 25 Mar, 2021
  • 1 location
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

This is an open-label, randomized, multicentric study in patients with high-risk non-muscle invasive bladder cancer who had never received BCG for this disease. The objective is to

bladder cancer
neutrophil count
metastasis
invasive bladder cancer
intravesical administration
  • 0 views
  • 07 Apr, 2021
  • 30 locations
Atezolizumab and BCG in High Risk BCG na ve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

Patients with high-risk non-muscle invasive bladder cancer (NMIBC) are usually managed by transurethral resection of their bladder tumor (TURBT) alone plus additional intravesical therapy to

bladder cancer
carcinoma
tumor cells
bacillus calmette-guerin
carcinoma of the bladder
  • 0 views
  • 25 Jan, 2021
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA) with or without chemotherapy. The study is comprised of two groups; dose optimization and dose expansion cohorts. Dose Optimization will include first-line and second-line melanoma, non-small cell …

metastatic urothelial carcinoma
cancer chemotherapy
immunologic adjuvant
solid tumour
lung cancer
  • 1682 views
  • 04 Jun, 2021
  • 67 locations
Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

Immunotherapy (checkpoint inhibitors) is approved as first and second line treatment to patients with metastatic bladder cancer. However, response rates are low and no biomarkers have yet shown

bladder cancer
radical cystectomy
metastatic bladder carcinoma
transitional cell carcinoma
carcinoma
  • 0 views
  • 27 Mar, 2021
  • 5 locations
Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer

This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks …

bladder cancer
radical cystectomy
aptt
white blood cell count
transitional cell carcinoma
  • 0 views
  • 22 May, 2021
  • 3 locations
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

The purpose of this study is to determine the good and bad effects of atezolizumab given in combination with a personalized cancer vaccine in patients with urothelial cancer either after surgery to remove organ where the tumor arose (for example, removal of the bladder) or for urothelial cancer that has …

metastatic urothelial carcinoma
bladder cancer
glomerular filtration rate
platelet count
carcinoma
  • 7 views
  • 15 Mar, 2021
  • 1 location
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy

bladder cancer
autoimmune disease
bcg vaccine
systemic chemotherapy
corticosteroids
  • 37 views
  • 13 Jun, 2021
  • 171 locations